Skip to main content
. Author manuscript; available in PMC: 2024 Jan 5.
Published in final edited form as: Clin Cancer Res. 2023 Jul 5;29(13):2445–2455. doi: 10.1158/1078-0432.CCR-22-3247

Figure 2: Genomic profile of patients with histiocytosis enrolled to the Make-an-IMPACT program and clinical benefit of genomically matched therapies.

Figure 2:

A. Oncoprint of potentially actionable genomic alterations in patients with histiocytosis.

B. Pre- and post-treatment fused axial FDG-PET/CT images of a patient with Erdheim- Chester Disease with a BRAF V600E mutant tumor. Pre-treatment PET (left) reveals symmetric, bilateral, intra-medullary FDG uptake involving the femoral condyles. Repeat PET imaging following 12 months of vemurafenib demonstrated a complete metabolic response.

C. Pre- and post-treatment images of a patient with Erdheim-Chester Disease with a NRAS A59_E79 in-frame deletion. Pre-treatment image (Left image) demonstrating extensive skin lesions. Marked flattening and regression of skin lesions following 3 months of cobimetinib (Right image).

D. Swimmers plot of patients with histiocytosis treated with targeted therapies selected based on their MSK-IMPACT results. Arrows designate ongoing treatment. Stars indicate the patients highlighted in B (red star) and C (yellow star).